DealsJul 14, 2026, 06:36 AM
Spero Licenses SP001 from Innovent; Upfront $35M, Milestones $1.05B
AI Summary
Spero Therapeutics entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready anti-CD40L antibody, gaining worldwide rights (excluding Greater China) for its development and commercialization. Spero will pay Innovent a $35 million upfront fee and up to $1.05 billion in milestones, with plans to initiate a Phase 2 trial for SP001 in IgG4-related disease in Q2 2027. Concurrently, Spero secured a $105 million non-recourse non-dilutive financing from Healthcare Royalty, backed by future Utebzi milestones and royalties, extending its cash runway into the second half of 2029 to fund SP001's development.
Key Highlights
- Spero Therapeutics licensed exclusive global rights (ex-Greater China) for SP001 from Innovent Biologics.
- Spero will pay Innovent a $35 million upfront payment for the SP001 license.
- Innovent is eligible for up to $1.05 billion in development, regulatory, and commercial milestones.
- Spero plans to initiate a Phase 2 trial for SP001 in IgG4-related disease in Q2 2027.
- Spero secured a $105 million non-recourse non-dilutive financing from Healthcare Royalty.
- The financing is backed by a portion of future Utebzi milestones and royalties.
- Spero updated its cash runway guidance into the second half of 2029.
Price Impact
More from SPRO